NEDA or "no evidence of disease activity" is emerging as a much discussed outcome measure, which has a much better connotation than reducing relapses, or slowing progression when discussing potential outcomes of therapy. But, is it offering us anything new in terms of efficacy, sensitivity or prognosis?
There are many criticisms of the current outcome measures-relapse frequency, magnetic resonance imaging (MRI) activity and Expanded Disability Status Scale (EDSS) progression: events are infrequent and differences in relapse rates between treatment and placebo groups are miniscule and almost without clinical meaning-at best 0.2 attacks per year. Typically, fewer than 10% of patients experience differences in EDSS progression within 2 years and analysis of trials fail to link measures such that there is no way of knowing whether patients failing to progress are the same as those not having relapses or MRI activity. Hence, the notion of being free of any of the outcomes becomes of interest, since it is presumed that if more patients on treatment compared to placebo fail to demonstrate relapse, MRI activity or EDSS progression then it must be attributable to the treatment. The problem with this logic is that 10-20% of the clinical trial placebo groups today are all showing NEDA; 1 so in the absence of a placebo group, being NEDA on a treatment may mean either an excellent treatment response, or a completely benign disease rendering treatment extraneous. And what of the other aspects of multiple sclerosis (MS) that are not listed as "activity" such as cognitive decline, fatigue, pain or quality of life measures? Clearly, these should count for something, especially since they might change appreciably despite being NEDA. That is why others have suggested adding another MRI metric to the list of disease activity-brain atrophy, 2 supposedly as a surrogate for all the unforeseen changes such as cognitive decline not traditionally picked up by the usual NEDA measures.
In this issue of Multiple Sclerosis Journal (MSJ), Damasceno et al. 3 look at a cohort of patients on various disease modifying agents who have remained free of detectable relapse for at least 3 months and were then followed for 2 years to evaluate whether measurement of brain atrophy using MRI, together with periodic cognitive assessments, correlate with being traditionally NEDA. They noted that only 31% of their 39 patients achieved NEDA status after 2 years, yet nearly 58% of those (7 of 12) showed significant decline in cognitive measures. Although there was slightly less grey matter atrophy in the NEDA group, this correlated only with having less MRI activity, not less cognitive change as they expected.
Aside from looking at combined effects of treatment on several outcomes, remaining NEDA for a period of time on medication might offer a prognostic indication, such as how likely it is to be NEDA in the future. Rotstein et al. 4 noted that 78% of their small cohort of patients achieving NEDA status at 2 years (only 27% of the initial patient group) continued their NEDA status at 7 years. Whether that group was also free of any worsening brain atrophy or cognitive change is unknown.
So what is NEDA offering us that other outcome measures are not? Assuming all can agree on a standardized fashion of assessing relapses, disease progression and MRI activity, as well as the frequency with which we do so, we will still be missing out on evaluating other important aspects of MS disease. Clearly, the more items we add, the greater the challenge to be free of "all" activity over time, and the longer you follow patients, the greater the likelihood that few will remain NEDA-and those that do, arguably may have benign disease rather than necessarily benefiting from medication. Some advocate adding brain atrophy to the fray and declare a "NEDA-4" vs. the traditional "NEDA-3" outcome measure, to reflect what might be cognitive change that has not been clinically measured. The current study of Damasceno et al. 3 suggests that brain atrophy would be more a reflection of MRI activity than of cognitive loss. Another recent study 5 corroborates that finding in showing that most of measured brain atrophy after a year was experienced by those who were "not NEDA" on medication, despite the finding of no difference in cognitive measures between them and the NEDA group.
It would appear that NEDA or NEDA+ (the + reflecting all the other imaginable measures of ongoing disease) is not quite ready for "prime time." Despite being a potential short-term goal for therapy, 2 it is a stretch to presume that a patient is doing well simply because they are not doing badly or because they are taking a particular medication. Perhaps that is more a reflection of the choice of measures to assess disease activity, since the more things you assess, the greater the chances of not being NEDA. And finally, we must always keep in mind that a patient's NEDA status, as unlikely as it may be, is a feature of a benign disease process-one that does not require any treatment at all.
